NuVasive on May 10 posted first quarter sales of $307.7 million.
Four notes:
1. Total sales were up 5.8 percent year-over-year, according to a news release. This was largely driven by growing adoption of new products and increased procedural volume in the U.S.
2. U.S. cervical spine sales saw its sixth consecutive quarter of greater than 20 percent growth. Thhis was driven by C360 and Simplify cervical disc sales.
3. NuVasive expects 2023 net sales to grow 6 percent to 8 percent.
4. NuVasive reported a net loss of $1 million.